top of page

June 30, 2026

Claude Science is an app that integrates the tools and packages that researchers most commonly use, produces auditable artifacts, and provides flexible access to computing resources.

AI has the potential to dramatically accelerate the pace of scientific discovery and the development of healthcare interventions. Since launching our efforts in the life sciences last fall, we’ve worked to improve our model capabilities, make connections to the scientific ecosystem via MCPs and skills, and launch partnerships in an effort to realize this potential.


Today, we’re introducing our most significant expansion of these efforts: Claude Science, an AI workbench for scientists. Claude Science is an app that integrates the tools and packages that researchers most commonly use, produces auditable artifacts, and provides flexible access to computing resources.


Introducing Claude Science

Scientific research is often tedious. Researchers must work across dozens of databases, each with their own schema, contend with file formats that require bespoke data pipelines and viewers, and transition between a roster of tools: PubMed, Jupyter, R, a cluster terminal, and more.


Claude Science brings these fragmented tools into a single research environment where scientists can conduct all stages of their work. It helps you analyze literature and execute multi-step research, produces detailed artifacts, and lets you iteratively refine figures and manuscripts until they’re ready for publication. Every output carries an auditable history of how it was made, so you can validate and reproduce the results. Like a Jupyter Notebook, you can access Claude Science wherever you already work—locally on macOS or Linux, or on a remote machine over SSH or with an HPC login node.


Users interact with a generalist coordinating agent with access to over 60 curated skills and connectors pre-configured for genomics, single-cell, proteomics, structural biology, cheminformatics, and more. These agents can spin up others and engage with specialist agents created by users. And a reviewer agent checks citations and calculations, flagging and correcting errors.


We are releasing Claude Science today in beta for Claude Pro, Max, Team, and Enterprise users, and will continue to refine the platform as we collect feedback from users.


How it works

Claude Science displays proteins, structures, and molecules natively, with every result reproducible and traced to its code.
Claude Science displays proteins, structures, and molecules natively, with every result reproducible and traced to its code.

Rich scientific artifacts, fully reproducible. Scientific research is inherently visual, so Claude Science generates figures and manuscripts alongside the code that created them. It natively renders rich scientific artifacts, including 3D protein structures, genome browser tracks, chemical structures, and more. You can chat with the agent about any detail, annotating figures and manuscripts in-line so the agent knows what to address to make them publication-ready.


When it generates a figure, Claude Science includes the exact code and environment that produced it, a plain-language description of how it was created, and the full message history. This allows you to understand the inputs, making the work easier to validate and reproduce even months later. You can ask Claude Science to make edits to figures in plain language—removing gridlines, for example, or changing an axis to log scale—and the agent will edit its own code.


Manages your compute and scales on demand. Large analyses—folding a protein, for example, or running a genomics pipeline over a massive dataset—often require researchers to shift their focus to setting up a computing job, waiting while it’s sent to a cluster, checking whether it succeeded or failed, and pulling the results back. Claude Science handles this process for you. It drafts a plan, asks before reaching new resources, and lets you review or revoke any decision before writing and submitting the job to the computing resources your lab already uses (your own HPC cluster over SSH, or your Modal account for compute on demand), scaling the analysis from a single GPU to hundreds as needed.


Because its agents work inside a running session that holds context in memory, even massive datasets only need to be loaded once. It runs on your lab’s own infrastructure—your laptop, Linux box, or HPC login node—so large or sensitive datasets never have to leave the systems they’re already on, and only the context needed for each step of the analysis is sent to Claude. As the pipeline runs, a reviewer agent inspects the outputs, flagging incorrect citations, untraceable numbers, and figures that don’t match their underlying code, and self-correcting as it goes. You can fork the session at any point to compare two approaches without losing the original thread.


Domain-ready on day one. Scientific knowledge is scattered across hundreds of specialized sources. In biology, for example, relevant data might sit across resources such as UniProt, PDB, Ensembl, Reactome, ClinVar, ChEMBL, GEO—each with its own schema and query language—as well as in journals and preprint servers, and domain-specific open models. When you ask Claude Science a question in plain language, specialist agents query and synthesize across all of these sources so you don’t have to navigate them individually. Claude Science uses the skills in NVIDIA’s BioNeMo Agent Toolkit to connect natively to the life sciences models and libraries in BioNeMo, including Evo 2, Boltz-2, and OpenFold3.


Scientists already have models, datasets, and pipelines they trust. Claude Science can connect to these as well, saving any pipeline as a reusable skill or accessing your lab’s preferred tool using a connector, with future sessions inheriting them automatically. This customizability allows you to access Claude, your proprietary data, and the validated tools you already rely on in one conversation. Claude Science benefits from our partners’ specialized expertise and platforms, while more scientists reach their tools through Claude.


What scientists are doing with Claude Science

Over the past few months, researchers have worked with Claude Science in beta for tasks like single-cell RNA sequencing analysis, CRISPR screen design, protein structure prediction, cheminformatics, and more.


Manifold Bio designs tissue-targeting medicines—which home to a specific organ or cell type, so the drug acts where it’s needed and spares the rest of the body—and tests how millions of candidate binders corresponding to hundreds of targets distribute through a living body at once. Manifold used Claude Science to nominate the targets for its latest experiments. For each tissue and target, Claude Science assessed surface expression, trafficking, and safety, ranking candidates against the criteria Manifold has learned from its own internal proprietary data. What set Claude Science apart from a general coding assistant, Manifold said, was that it could do this end-to-end, gathering the right data and applying the right judgment with the context of past programs built in.


Jérôme Lecoq, a neuroscientist at the Allen Institute, used Claude Science to build a multi-agent “computational review template” comprising about 20 custom skills geared towards writing long-form reviews. The sub-agents read through thousands of papers, pulling the central claim and the key quantitative finding, and storing them in an evidence state database. Then the pipeline constructs a narrative arc, writing the review section by section and delegating each to its own specialized sub-agent. Within each section, dedicated agents generate quantitative cross-study figures directly from the evidence database. A key component of the workflow, enabled by Claude Science, is the use of actor-critic pairs: one agent creates content while a separate reviewer agent evaluates it for accuracy and citation fidelity.


Before Claude Science, it could take Lecoq’s team as many as two years to write such a review. He now has about 10 reviews, many more than 100 pages, with citations that were checked over by reviewer agents. The team is now working with domain experts to further refine the AI-based critic agents.


And Stephen Francis, an associate professor and epidemiologist at the UCSF Brain Tumor Center, has used Claude Science to support studies on the molecular epidemiology of glioma, a type of primary tumor that begins in the glial cells of the brain. His lab investigates the genetic basis for how thousands of small-effect germline variants combine to shape individual susceptibility. Although this work predated Claude Science, Francis said the app has dramatically accelerated the analysis, enabling comprehensive germline workups across multiple approaches in roughly one-tenth the time it previously took. His group independently validated Claude Science’s results, confirming that it can produce both rapid and robust analyses.


Getting started with Claude Science

The Claude Science app is available in beta on macOS and Linux for Pro, Max, Team, and Enterprise plans. We’re sharing it early so scientists can start to use it on real problems and tell us how to refine it.


Team and Enterprise users will need their admin to enable Claude Science. We now have a Team plan offering discounted seats for active scientific labs at academic institutions and nonprofit research organizations; learn more here.


We’ll also be supporting up to 50 Claude Science AI for Science projects, providing up to $30,000 in credits. Modal will also be providing up to $2,000 in compute for select projects. We are looking for projects that span domains and explore the boundaries of science, with an early focus on biology and biomedical research. Applications are open through July 15, 2026, with award notifications sent out by July 31. Projects will run from September 1 to December 1, 2026—apply here.


To stay up-to-date on product announcements, provide feedback, and learn from others in the Claude Science community, join the AI for Science Discourse community.


Get started with Claude Science at claude.com/science.





January 08, 2024. BEIJING, China

Company Vision - To become a first-class new energy unicorn enterprise rooted in China and looking to the world

Betavolt atomic energy batteries can generate electricity stably and autonomously for 50 years without the need for charging or maintenance. They have entered the pilot stage and will be put into mass production on the market. Betavolt atomic energy batteries can meet the needs of long-lasting power supply in multiple scenarios such as aerospace, AI equipment, medical equipment, MEMS systems, advanced sensors, small drones and micro robots. This new energy innovation will help China gain a leading edge in the new round of AI technological revolution.


Beijing Betavolt New Energy Technology Co., Ltd. announced on January 8 that it has successfully developed a miniature atomic energy battery. This product combines nickel -63 nuclear isotope decay technology and China's first diamond semiconductor (4th generation semiconductor) module to successfully realize the miniaturization of atomic energy batteries. , modularization and low cost, starting the process of civilian use. This marks that China has achieved disruptive innovation in the two high-tech fields of atomic energy batteries and fourth-generation diamond semiconductors at the same time, putting it "way ahead" of European and American scientific research institutions and enterprises.



Betavolt atomic energy batteries can generate electricity stably and autonomously for 50 years without the need for charging or maintenance. They have entered the pilot stage and will be put into mass production on the market. Betavolt atomic energy batteries can meet the needs of long-lasting power supply in multiple scenarios such as aerospace, AI equipment, medical equipment, MEMS systems, advanced sensors, small drones and micro-robots. This new energy innovation will help China gain a leading edge in the new round of AI technological revolution.


Atomic energy batteries, also known as nuclear batteries or radioisotope batteries, work on the principle of utilizing the energy released by the decay of nuclear isotopes and converting it into electrical energy through semiconductor converters. This was a high-tech field that the United States and the Soviet Union focused on in the 1960s . Currently, there are only thermonuclear batteries used in aerospace. This type of battery is large in size and weight, has high internal temperatures, is expensive, and cannot be used by civilians. In recent years, miniaturization, modularization and civilian use of nuclear batteries have been the goals and directions pursued by European and American countries. China's "14th Five-Year Plan and 2035 Vision Goals" also propose that the civilianization of nuclear technology and the multi-purpose development of nuclear isotopes are future development trends.


Betavoltaic nuclear batteries develop a completely different technological approach, generating electric current through the semiconductor transition of beta particles (electrons) emitted by the radioactive source nickel -63 . To do this, Betavolt's team of scientists developed a unique single-crystal diamond semiconductor that is just 10 microns thick, placing a 2- micron-thick nickel -63 sheet between two diamond semiconductor converters. The decay energy of the radioactive source is converted into an electrical current, forming an independent unit. Nuclear batteries are modular and can be composed of dozens or hundreds of independent unit modules and can be used in series and parallel, so battery products of different sizes and capacities can be manufactured.


Zhang Wei, chairman and CEO of Betavolt , said that the first product the company will launch is BV100 , which is the world's first nuclear battery to be mass-produced. The power is 100 microwatts, the voltage is 3V , and the volume is 15 X 15 X 5 Cubic millimeters are smaller than a coin. Nuclear batteries generate electricity every minute, 8.64 joules per day, and 3153 joules per year. Multiple such batteries can be used in series and parallel. The company plans to launch a 1- watt battery in 2025. If policies permit, atomic energy batteries can allow a mobile phone to never be charged, and drones that can only fly for 15 minutes can fly continuously.



According to reports, the atomic energy battery is a physical battery, not an electrochemical battery. Its energy density is more than 10 times that of ternary lithium batteries. It can store 3,300 megawatt hours in a 1- gram battery . It will not catch fire or explode in response to acupuncture and gunshots. Because it generates electricity automatically for 50 years, there is no concept of the number of cycles of an electrochemical battery ( 2000 charges and discharges). The power generation of atomic energy batteries is stable and will not change due to harsh environments and loads. It can work normally within the range of 120 degrees above zero and -60 degrees below zero, and has no self-discharge. The atomic energy battery developed by Betavolt is absolutely safe, has no external radiation, and is suitable for use in medical devices such as pacemakers, artificial hearts and cochleas in the human body. Atomic energy batteries are environmentally friendly. After the decay period, the nickel -63 isotope as the radioactive source becomes a stable isotope of copper, which is non-radioactive and does not pose any threat or pollution to the environment. Therefore, unlike existing chemical batteries, nuclear batteries do not require expensive recycling processes.


Currently, Betavolt has registered a patent in Beijing and will begin to register global PCT patents. In the 2023 Innovation Competition held by China National Nuclear Corporation, Betavolt, as one of the very few external participating companies, stood out among hundreds of companies and research institutions and won the third prize in the competition. It represents China's authoritative nuclear technology companies' investment in Betavolt. Recognition of atomic energy battery technology and products. Betavolt has also communicated with China's professional nuclear research institutions and universities, and plans to continue research on using isotopes such as strontium- 90 , promethium- 147 and deuterium to develop atomic energy batteries with higher power and a service life of 2 to 30 years.


Zhang Wei said that the core of Betavolt atomic energy battery is the fourth generation diamond semiconductor, which is the ultimate semiconductor material well known in the industry and another high ground in the global semiconductor field technology competition. Betavolt is currently the only company in the world that can dope large-size diamond semiconductor materials. High-efficiency diamond converters are the key to manufacturing nuclear batteries. Betavolt is not only a new energy company, but also a fourth-generation semiconductor and ultra-long carbon nanotube new material company. Nuclear batteries, diamond semiconductors and supercapacitors are the three major technologies and materials that are linked and integrated to form Betavolt's core technology and innovation capabilities.


For more technical and product information about Betavolt,

Login website: www.betavolt.tech,

Thank you for your inquiry and attention.



d

Company Vision - To become a first-class new energy unicorn enterprise rooted in China and looking to the world

November 11th, 2021. TOKYO, Japan.

The project will assess the mitigation strategy for up to three large debris objects with a single servicer in low Earth orbit and will aim to further demonstrate the viability of commercial debris removal while advancing the state of orbital sustainability.

Astroscale Holdings Inc. (“Astroscale”), the market leader in satellite servicing and long-term orbital sustainability across all orbits, today announced it has signed a Memorandum of Understanding with New Zealand’s Ministry of Business Innovation & Employment (“MBIE”) to cooperate on areas of space safety and sustainability, including debris mitigation and remediation, and on-orbit servicing in general.



The collaboration is focused on partnership in projects and activities that support long-term space sustainability, including joint technology development and research. To initiate these efforts, Astroscale and MBIE have identified an initial project in collaboration with Rocket Lab and Te Pūnaha Ātea–Auckland Space Institute, which will define the engineering requirements, policy challenges and associated costs for multi-active debris removal missions with clients that require direct re-entry due to survivability of components. The project will assess the mitigation strategy for up to three large debris objects with a single servicer in low Earth orbit and will aim to further demonstrate the viability of commercial debris removal while advancing the state of orbital sustainability.

[ Astroscale & MBIE Virtual Signing Ceremony on November 11, 2021 ]


“Space sustainability is a global concern that requires international collaboration between industry and government. This partnership with the Government of New Zealand underscores the potential to advance the technical, regulatory and business case solutions needed to solve this challenging problem,” said Chris Blackerby, Group COO of Astroscale. “Astroscale and the Government of New Zealand share a vision for improved space situational awareness and developing on-orbit servicing. We prioritize safety and collaboration in support of the rapidly growing orbital economy and are thrilled to join forces to explore new opportunities for sustainable growth.”


“Astroscale’s cutting-edge technology, combined with their approach to space sustainability matches perfectly with our values as a nation. For New Zealand this creates new commercial opportunities, and builds the skills and capability of our people,” said Paul Stocks, Deputy Secretary Labour, Science and Enterprise of MBIE. “This partnership underlines our approach to the use of space – partnering with the best firms and researchers, to solve big global challenges and enable ground-breaking research and development. We look forward to working with Astroscale to develop and expand the New Zealand space industry, and continue to explore new opportunities for collaboration.”


[ L-R: Joe McKay, Manager, Strategic Partnership, Paul Stocks, Deputy Secretary Labour, Science and Enterprise, and Kjesten Wiig, Director Innovative Partnerships ]



_edited.png

A socio-corporate media platform of highlights on company news and industry events. Opinions of interests are key for post-productions in support from ASR TV.

© 2026 Alexander Solomon Report 

HomeT&C Privacy PolicyCookie Policy │Modern Slavery

bottom of page